ArticleLeukemia2019
KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.
Open access · hybridAbstract readLetter
In one paragraph
Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Early experience with cerebrospinal fluid cell-free DNA molecular profiling in a neuro-oncology practice.Journal of neuro-oncology · 2026Article
- Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype.British journal of haematology · 2026Article
- BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance.Current hematologic malignancy reports · 2026Review
- Article
- Landscape of BRAF transcript variants in human cancer.Molecular oncology · 2025Article
- Network pharmacology and AI in cancer research uncovering biomarkers and therapeutic targets for RALGDS mutations.Scientific reports · 2025Article
- Prioritizing cervical cancer candidate genes using chaos game and fractal-based time series approach.Theory in biosciences = Theorie in den Biowissenschaften · 2024Article
- Integrative Analysis of Multi-Omics Data to Identify Deregulated Molecular Pathways and Druggable Targets in Chronic Lymphocytic Leukemia.Journal of personalized medicine · 2024Article
- Leveraging genomics, transcriptomics and epigenomics to understand chemoimmunotherapy resistance in chronic lymphocytic leukemia.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.Frontiers in oncology · 2024Review
- Deciphering Conformational Changes of the GDP-Bound NRAS Induced by Mutations G13D, Q61R, and C118S through Gaussian Accelerated Molecular Dynamic Simulations.Molecules (Basel, Switzerland) · 2022Article
- Review
- KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders.Cancers · 2022Review
- Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets.Cancers · 2021Review
- TargetingCancers · 2021Review
- Consistent B Cell Receptor Immunoglobulin Features Between Siblings in Familial Chronic Lymphocytic Leukemia.Frontiers in oncology · 2021Article
- Neoantigens in Hematologic Malignancies.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 2 countries.
Elena VendraminiClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy.
Riccardo BombenClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy.
Federico PozzoClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy.
Dania BenedettiClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy.
Tamara BittoloClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy.
Francesca Maria RossiClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy.
Michele Dal BoClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy.
Kari G RabeDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Gabriele PozzatoDepartment of Internal Medicine and Haematology, Maggiore General Hospital, University of Trieste, Trieste, Italy.
Francesco ZajaDepartment of Internal Medicine and Haematology, Maggiore General Hospital, University of Trieste, Trieste, Italy.
Annalisa ChiarenzaDivision of Hematology, Ferrarotto Hospital, Catania, Italy.
Francesco Di RaimondoDivision of Hematology, Ferrarotto Hospital, Catania, Italy.
Esteban BraggioDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Sameer A ParikhDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Neil E KayDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Tait D ShanafeltDepartment of Hematology/Oncology, Stanford University, Stanford, CA, USA.
Giovanni Del PoetaDivision of Hematology, S. Eugenio Hospital and University of Tor Vergata, Rome, Italy.
Valter GatteiClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy. vgattei@cro.it.
Antonella ZucchettoClinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy. zucchetto.soecs@cro.it.
Centro di Riferimento Oncologico · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITMayo Clinic in Arizona · USFerrarotto Hospital · ITUniversity of Trieste · ITMayo Clinic in Florida · USStanford University · USSt. Eugenio Hospital · IT
Funding
Predicting clinical outcome in individuals with small CLL B cell clonesR01CA197120 · NCI · MAYO CLINIC ROCHESTER · PI KAY, NEIL E, SHANAFELT, TAIT D · 2015 to 2019
$3.0MNCI NIH HHS R01 CA197120
Abstract
PubMed holds no abstract for this paper.
Indexed as
Chromosomes, Human, Pair 12MutationTrisomyAdultAgedFemaleGTP PhosphohydrolasesHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMembrane ProteinsMiddle AgedProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)BRAF protein, humanGTP PhosphohydrolasesKRAS protein, humanMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.